Application of Caco-2 cell line in herb-drug interaction studies : current approaches and challenges by Awortwe, C. et al.
J Pharm Pharm Sci (www.cspsCanada.org) 17(1) 1 - 19, 2014 
1 
Application of Caco-2 Cell Line in Herb-Drug Interaction Studies: Current 
Approaches and Challenges 
C. Awortwe1, P.S. Fasinu2, B. Rosenkranz1 
1 Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, University of Stellenbosch, Tygerberg, Cape 
Town, South Africa. 2 National Center for Natural Products Research, School of Pharmacy, University of Mississippi, Oxford, 
USA. 
Received, August 23, 2013; Revised, December 27, 2013; Accepted, January 4, 2014; Published, January 6, 2014. 
ABSTRACT - The Caco-2 model is employed in pre-clinical investigations to predict the likely gastrointestinal 
permeability of drugs because it expresses cytochrome P450 enzymes, transporters, microvilli and enterocytes of 
identical characteristics to the human small intestine. The FDA recommends this model as integral component of 
the Biopharmaceutics Classification System (BCS). Most dedicated laboratories use the Caco-2 cell line to screen 
new chemical entities through prediction of its solubility, bioavailability and the possibility of drug-drug or herb-
drug interactions in the gut lumen. However, challenges in the inherent characteristics of Caco-2 cell and inter-
laboratory protocol variations have resulted to generation of irreproducible data. These limitations affect the 
extrapolation of data from pre-clinical research to clinical studies involving drug-drug and herb-drug interactions. 
This review addresses some of these caveats and enumerates the plausible current and future approaches to reduce 
the anomalies associated with Caco-2 cell line investigations focusing on its application in herb-drug interactions. 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________ 
INTRODUCTION  
Oral administration of drugs and xenobiotics is the 
most convenient route of drug administration  (1,2). 
Oral drug absorption is complex; characterized by 
multiple challenges including the inherent 
characteristics of the formulation, the physiological 
conditions and the physicochemical properties of the 
drugs (3) . Additionally, intestinal enterocytes 
present a well-structured defensive system to 
modulate entry of drugs and xenobiotics from gut 
lumen into the systemic circulation. Metabolism and 
transport of drugs across intestinal membrane are 
therefore multifaceted and dynamic process 
involving both passive and active transport 
mechanisms (Figure 1). Hence, transmembrane 
absorption is generally recognized as a basic 
condition to ensure efficient systemic availability of 
drugs via the gastro-intestinal tract. 
Research scientists and pharmaceutical 
companies employ cell-based assays such as Caco-2 
cells and Mardin-Darby canine kidney (MDCK); 
artificial lipid-based systems including parallel 
artificial membrane permeability assay (PAMPA) as 
preclinical high throughput screening models for  
evaluation of intestinal permeability of drugs and 
herbal supplements (4,5,6,7). The Caco-2 cell line 
derived from human colon adenocarcinoma is 
considered the most common in vitro model used for 
investigation and prediction of intestinal drug 
absorption  (8) . It undergoes spontaneous enterocytic 
differentiation in appropriate culture to become 
polarized cells expressing apical and basolateral 
surfaces with well-established tight junctions. The 
polarized cells depict several functions of normal 
enterocytes including expression of brush border 
enzymes, some cytochrome (CYP) isoenzymes and 
phase II enzymes (9). The model is also employed in 
identification of substrates and/or inhibitors of drug 
transporters  (10) . Caco-2 cell line is used for 
screening of conventional drugs and new chemical 
entities for potential drug-drug interactions. 
However, its application in most dedicated 
laboratories and research institutions for screening 
herbal medications for likely herb-drug interactions 
is gaining popularity. 
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In recent years, consumption of herbal remedies 
either in combination with conventional drugs or 
alone has become a common practice in patients 
suffering from chronic diseases such as HIV/AIDS 
and cancer  (11,12). Unfortunately, most physicians 
are unaware of this habit which may likely cause 
therapeutic failure and/or toxicity due to high 
propensity of such individuals experiencing herb-
drug interactions (13). 
Currently, studies on herb-drug interactions have 
increased due to the awareness of the possible threats 
it may pose to both patients and healthcare providers 
in an attempt to achieve optimum therapeutic 
objectives. The pharmacokinetic herb-drug 
interactions are mostly attributed to inhibition or 
induction of drug metabolism enzymes and 
transporters or renal drug clearance. The use of 
Caco-2 cell line to screen herbal remedies for 
possible herb-drug interactions may reduce the 
probability of associated therapeutic failure, adverse 
effects, and cost of treatment and withdrawal of 
herbal products from the market. 
Although most researchers and pharmaceutical 
industries prefer Caco-2 as an in vitro model for 
investigation of intestinal drug absorption, mixed 
reports have been published regarding its in vivo 
correlation with humans (14). The deficiencies 
associated with Caco-2 cell line as a preclinical 
model for prediction of intestinal permeability may 
yield inaccurate results in herb-drug interactions 
investigations. This review aims to appraise the 
utilization of Caco-2 cell lines in preclinical studies, 
address some of the associated limitations and the 
emerging approaches to resolve these problems. The 
emerging approaches addressed in this review may 
be beneficial to minimize current and future 
challenges likely to undermine the application of 
Caco-2 cell line for herb-drug interaction studies.    
Search strategy and selection criteria 
The review was conducted systematically by 
searching the databases of EBSCOHOST, 
MEDLINE, PUBMED, EMBASE, GOOGLE 
SCHOLAR, and COCHRAINE libraries for original 
researches that include the following combination 
search terms: “Caco-2 cell line”, “drug permeability 
and/or absorption”, “herb-drug interactions”, 
“pitfalls and current approaches”. The literature 
searches were limited to publications that are 
available online in English language. There was no 
limitation to dates of publication nevertheless in 
cases of recurrence of search results, the most recent 
was preferred.  
Mechanisms of intestinal drug absorption	
Absorption of herbal supplements and drugs mainly 
occurs at the duodenum and jejunum segments of 
small intestine due to high concentrations of villi and 
microvilli which provide a large surface area (15, 16, 
17, 18). The epithelial cells in these regions are 
heterogeneous with enterocytes responsible for the 
absorption of most pharmacological agents. The 
enterocytes are polarized with distinct apical and 
basolateral membranes separated by tight junctions. 
This architectural composition of polarized 
enterocytes restricts the passage of drugs and 
xenobiotics through either passive diffusion or 
carrier-mediated processes (19). The large surface 
area serves as a conduit for efficient permeation of 
drugs through various mechanisms including passive 
and active pathways. Passive diffusion encompasses 
two routes: the paracellular pathway which 
facilitates permeation of hydrophilic drugs of low 
molecular weight and peptides via aquaporins at the 
tight junctions between the enterocytes; and the 
transcellular pathway responsible for movement of 
lipophilic drugs across lipid cell membrane of the 
enterocytes. Presence of tight junctions in the 
intercellular space limits the free flow of compounds 
traversing the intestinal epithelium via the 
paracellular process (20). The carrier-mediated 
transport processes involve both facilitated and 
active mechanisms engineered by transport proteins 
responsible for uptake or efflux of drugs in the 
intestine as shown in figure 1 (21,22, 23). 
Uptake and efflux transporters are localized at 
both the apical side and basolateral membranes of the 
intestinal enterocytes. Efflux transporters commonly 
expressed in the intestine membranes include P-
glycoprotein (P-gp), multidrug resistance proteins 
(MRP 1–6), and breast cancer resistance protein 
(BCRP). These are members of the ATP-binding 
cassette (ABC) transport proteins which utilise ATP 
as energy source to transport substrates against a 
concentration gradient  (24,25,26) from the 
cytoplasm of intestinal cells back to the intestinal 
lumen or to the blood. 
Primary active efflux transporters notably P-gp, 
MRP2, and BCRP are well expressed on brush-
border apical membrane of the enterocytes and 
reported to form major hindrance to intestinal 
absorption of drugs  (27,28). (29,30).
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Figure 1. Pathways of drug absorption through intestinal enterocytes modified from Sugano et al. (27): carrier-mediated 
uptake (CMU), carrier-mediated efflux (CME), absorptive direction (A to B) and excretive direction (B to A). 
 
These have the tendency to reduce oral 
bioavailability of specific drugs by expulsion from 
the enterocytes into intestinal lumen. P-gp is a well-
recognized efflux transporter which influences 
absorption and excretion of several drugs due to its 
wider range of substrate specificity (31). BCRP is 
capable to extrude glucuronides and sulfate 
conjugates formed in the enterocytes into the lumen, 
although its main function relates to excretion of 
drugs and xenobiotics into breast milk and a 
defensive role at the placental barrier (32). MRP2 
plays an important role in detoxification of drug and 
xenobiotics which have undergone phase II 
metabolism to facilitate excretion  (33,34). Unlike 
efflux transporters, apical membrane uptake 
transporters increase absorption of drugs from the 
lumen into the enterocytes  (35,36). Finally, receptor-
mediated endocytosis could also play a role in drug 
absorption. 
Uptake transporters e.g., peptide transporter 
(PEPT), organic anion transporter (OAT), organic 
anion transporting polypeptide (OATP), organic 
cation transporter (OCT) are members of solute 
carrier (SLC and SLCO) superfamilies and function 
independent of ATP but rather transport drugs 
according to their concentration gradient (Figure 2). 
In the Caco-2 cell permeability assessment of 
drugs and herbal supplements, adequate expression 
of transport proteins can be utilized to predict the 
possible degree of bioavailability upon co-
administration (37). Most transporters 
aforementioned can be expressed in Caco-2 cell 
under appropriate culture media. Table 1 below 
describes the uptake and efflux transporters that are 
likely to be expressed in the Caco-2 cell line. Despite 
the possibility of expression of most transporters in 
the Caco-2 cell, some transporters like hPEPT1 are 
poorly developed except under modified conditions 
such as tease out or molecularly engineered 
manipulations. Few of these limitations will be 
subsequently discussed in detail. 
 
Caco-2 cell line 
The Caco-2 cell line is the most common and 
extensively characterized cell-based model for the 
assessment of absorption of drugs via the intestinal 
membrane enterocytes  (38, 39, 40). 
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Figure 2. Localization of ABC and SLC transporters in human small intestine adapted from Smetanová et al. (38)  
 
 
It is derived from heterogenous human epithelial 
colorectal adenocarcinoma cells, developed through 
research by Jorgen Fogh (1975) at Sloan-Kettering 
Institute for Cancer Research (41). The Caco-2 cells 
have the intrinsic ability to initiate spontaneous 
differentiation on reaching confluence in the 
presence of normal culture conditions. At 
confluence, there is progressive development of 
brush border. The surface occupied by each cell 
gradually reduces from 5 to 20 days post-confluence 
and intimate intercellular junctions are developed. 
During the same period, the length and density of 
microvilli increase. The Caco-2 cells form well - 
developed tight junctions after 21 days of culturing. 
At day - 30 post-confluence, the cell surface reaches 
minimum with typical enterocytes-like morphology. 
Most cells develop complete brush borders with tall 
and regular microvilli when the full structural 
polarization is achieved after 30 days (42) . The 
complete polarized Caco-2 cells resemble human 
small intestinal mucosa cells expressing brush 
borders, tight junctions and, efflux and uptake 
transporters at both apical and basolateral 
compartments. 
The Caco-2 cell line fairly represent intestinal 
biochemical barrier due to expression of membrane 
efflux proteins (P-gp, MRP 1-3), CYP450 
isoenzymes and phase II conjugating enzymes such 
as sulfotransferase, UDP-glucuronyltransferase, 
glutathione S-transferase (43,44) . Table 2 
summarizes the characteristics of a parental Caco-2 
cell line. Permeability of substrate via the Caco-2 
cell monolayer has proven to correlate closely with 
oral absorption in humans compared with other 
parental cell-based models. Currently, Caco-2 
monolayers are applied for screening the potential 
effects of herbs and new chemical entities (NCE) on 
absorption of drugs. 
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Table 2. Characteristics of Caco-2 cell line 
Parameter  Description  
Origin Human colorectal adenocarcinoma 
Growth in culture Monolayer epithelial cells 
Differentiation 14-21 days after confluence in standard culture medium 
Morphology Polarised cells, with tight junctions, apical brush border 
Electrical resistance High transepithelial electrical resistance (TEER) 
Digestive enzymes Typical membranous peptidases and disaccharidases of the small 
intestine 
Active transport Amino acids, sugars, vitamins, hormones 
Membrane ionic transport Na+/K+ ATPase, H+/K+ ATPase, Na+/H+ exchange, Na+/K+/Cl-. co-
transport, apical Cl-. channels 
 
 
Comparison of Caco-2 with other cell-based 
models for intestinal permeability studies 
The Madin-Darby canine kidney (MDCK) is 
considered as an alternative to Caco- 2 cell for 
permeability studies. The MDCK cell line is derived 
from the normal dog kidney. When cultured in an 
appropriate media, MDCK differentiate into 
columnar epithelial cells with clear tight junctions 
similar to Caco-2 formed within on a semi-
permeable membrane. The differentiated MDCK 
cell maintains characteristics of kidney epithelial 
cells such as asymmetric distribution of enzymes and 
vectorial transport of sodium and water from the 
apical to the basolateral membrane  (45). The MDCK 
has a shorter cultivation period (3 - 5 days) compared 
to 21 days of Caco -2 cell line. Furthermore, the 
transepithelial electrical resistance (TEER) of 
MDCK cells is lower and closer to that of small 
intestine compared to Caco-2 cell. This often results 
in a higher permeability coefficient of hydrophilic 
compounds in MDCK cells than Caco-2 cell. The 
shorter culture duration is advantageous since it 
reduces cost, time, and enhances high throughput. 
The MDCK cell line appears to be more robust and 
need less rigorous nutritional schedule over a short 
incubation period relative to Caco-2 cell. However, 
these cells are derived from dog kidney and therefore 
there is a high propensity of differences in the 
expression levels of some transporters and metabolic 
activity as compared to Caco-2 cell  (46). 
LLC-PK1 cells derived from pig kidney 
epithelial have also been employed as an alternative 
model to Caco-2 cells for assessing permeability of 
test compounds. Studies have reported the use of 
LLC-PK1 for characterization of passive absorption 
of test compounds  (47,48,49). 
The human adenocarcinoma HT29-MTX model 
is used to investigate the role of intestinal mucus on 
drug absorption across the intestinal barrier. The 
HT29-MTX is conditioned to acquire the 
morphological and mucin producing features of 
goblet cells by culturing parental HT29 in a medium 
containing 10-6M methotrexate for six months 
(50,51). Unlike Caco-2, HT29-MTX develops sparse 
microvilli on the apical side and reaches confluence 
3 days later than the former. However, expression of 
goblet cells in HT29-MTX increases absorption of 
lipophilic compounds compared to Caco-2 
monolayer. 
TC-7, a subclone of Caco-2 cells, is also used for 
permeability screening of tests compounds. The TC-
7 clone displays morphological features of brush-
border membrane, microvilli and tight junctions 
similar to Caco-2 monolayer (19). There is a good 
correlation of passive transcellular absorption of 
compounds through TC7 and the parental Caco-2 
cell monolayer comparable to the extent of 
permeability in humans. The TC-7 model therefore 
offers an alternative to Caco-2 for intestinal 
permeability assessment of test compounds. In 
addition, TC-7 has an advantage over Caco-2 by 
expressing high levels of CYP3A4 enzymes well 
represented in the intestine. However, TC-7 unlike 
Caco-2 cell lacks transport proteins and therefore its 
application is skewed towards metabolism of drug 
employing CYP3A4. 
2/4/A1 originates from fetal rat intestine and is 
considered to mimic intestinal passive paracellular 
permeability in humans better than Caco-2 
monolayer (52,53). This immortalized cell is 
reported to differentiate monolayers with tight 
junctions, brush-border membrane enzymes and 
transporter proteins. Unlike, Caco-2, tight junctions 
expressed in 2/4/A1 are loose and better for studies 
of compounds absorbed in the human intestine via 
the paracellular route. The model has been proven to 
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be excellent for prediction of poorly absorbed 
compounds such as mannitol and creatinine better 
than Caco-2 but comparable to that of human 
jejunum (52,53). Table 3 summarises the 
comparison of Caco-2 with other cell-based models 
for intestinal permeability analysis. 
 
Generalized Caco-2 cells study protocol 
Caco-2 Cell Culture  
Caco-2 cells are seeded in standard cell culture 
medium (consisting of Dulbecco’s modified Eagle’s 
medium supplemented with fetal bovine serum, 
nonessential amino acids, penicillin, and 
streptomycin) onto 24 transwell membrane inserts at 
specified cells concentration under a temperature of 
37oC in an atmosphere of 5% CO2 and 90% relative 
humidity.  The cell monolayers are employed for 
transport studies 15 - 21 days after seeding between 
different passages (54).  
 
Cell viability  
Caco-2 cells are seeded onto Petri dishes (area 9.2 
cm2) at a density of 2 x 105 cells/cm2 and cultured for 
24 h. Investigated compound or transport medium 
(control) is added and incubated for 2 h. The cells are 
then released from the dishes and incubated with 
0.4% Trypan blue for 5 min and counted under a 
microscope (55). 
 
Assessment of monolayer integrity 
The integrity of Caco-2 cell monolayer can be 
determined by monitoring the paracellular 
permeability of ion and hydrophilic compounds 
using TransEpithelial Electrical Resistance (TEER) 
and 14C-mannitol respectively after the experiment. 
Mannitol is water soluble, cell membrane 
impermeable and non-ionisable small molecule with 
molecular weight of 182 g/mol and radius 4.1 nm. 
The low permeability of mannitol (<0.5% per hour) 
is used as a criterium to determine integrity of the 
Caco-2 monolayer. It is imperative to assess the 
integrity of the monolayer with 14C-mannitol after 
the actual permeability experiment or during the 
permeability experiment in the absence and presence 
of test compounds and control. TEER provides faster 
and reliable alternative method of assessing Caco-2 
cell monolayer intensity. The TEER of monolayer is 
measured post equilibrating the monolayer in a 
transport buffer with ERS Voltmeter. The integrity 
of the monolayer is confirmed by measuring the 
TEER after each permeability experiment  (56). 
 
Test compound
Caco-2 tool transwell plate
: apical - basolateral transport
: basolateral -apical transport
Transwell insert
Cell monolayer
Permeable membrane
Apical 
chamber
Basolateral
chamber
  
 
 
Figure 3. Caco-2 cell in transwell plate (57) 
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Bidirectional transport assay 
Prior to all experiments, the inserts (figure 3) are 
washed twice and equilibrate with pre-warmed 
transport medium at 37oC for 30 min. The transport 
experiment is initiated by addition of diluted probe 
substrate (positive control) in the presence or 
absence of the test substrate to either the apical (for 
apical to basolateral transport; AP - BL) or 
basolateral (for basolateral to apical transport; BL - 
AP) side of the monolayer. The monolayers are then 
placed in an incubator at 37°C. The samples are 
withdrawn from either compartment at different time 
intervals (e.g. 30, 60, 90 and 120 min) for H PLC 
analysis or liquid scintillation spectrometry 
(58,59,60).  
Data analysis of transport 
The apparent permeability coefficient, Papp (cm/s) 
is determined as: 
݌௔௣௣	ୀ	ቀఋொ ఋ௧ൗ ቁൈ൫ଵ ஺ൗ ൈ ஼೚൯
Where δQ δtൗ is the permeability rate, the amount ofdrug appearing in the receiver as a function of time 
(nmol/s), ܥ௢ is the initial concentration in the donor chamber (nmol/ml), and A is the surface area of the 
monolayer (cm2) as published by Engdal and Nilsen 
(37). 
The direction of probe substrate transport in the 
monolayer can be determined as passive or active 
using the Papp uptake ratio: 
Pappuptake ratio= Papp ൬AP-BLBL-AP൰ 
The net substrate flux can be calculated as the 
difference between the B–A and the A–B flux, J: 
ܬܰ݁ݐ ൌ ܬሺܤ െ ܣሻ െ ܬሺܣ െ ܤሻሺ݊݉݋݈	ܿ݉ିଶ݄ିଵሻ 
Where: J= Papp*Co൫nmol cm-2h-1൯ 
Percentage inhibition is calculated according to:  
%inhibition= ൬100- JNet, inhibitionJNet, control ൰×100 
Evidence of herb-drug interactions in Caco-2 cell 
model at transporter level 
The Caco-2 cell model is capable of expressing 
intestinal efflux and uptake transporters which 
regulate permeation of drugs, and herbs from 
intestinal lumen to systemic circulation. Herbal 
remedies contain numerous phytochemical 
compounds with functional groups identical to those 
found in conventional drugs. The availability of 
compounds with similar functional groups in both 
herbal medicines and drugs causes substrate overlap 
at receptor sites to generate herb-drug interactions 
when co-administered (61,62). Clinical studies have 
reported impact of herb-drug interactions on 
disposition of therapeutics in patients and healthy 
individuals. For example, the most common 
implicated herbal medicine, St. John’s wort (SJW) is 
reported to reduce bioavailablity of different drugs 
including digoxin (63, 64,65), amitriptyline (66), oral 
contraceptives (ethinyl estradiol and norethindrone) 
(67), or cyclosporine (68,69, 70, 71, 72, 73, 74, 75, 
76) . The widespread effect of SJW on drugs for
management of diverse pathological conditions has 
been attributed to the induction of P-gp by a 
bioactive compound hyperforin, modulating the 
expulsion of these drugs from enterocytes into the 
intestinal lumen. The Caco-2 cell line is used as a 
pre-clinical model to predict the possibility of herb-
drug interactions ex vivo subsequent to clinical trials. 
The prediction of drug-drug and herb-drug 
interactions involving drug transporters is inferred 
from pre-clinical evidence from cell lines and animal 
models.  In vitro studies have shown that, green tea, 
garlic and milk thistle extracts inhibit activity of P-
gp (77,78,79)  whilst genisten, a bioactive compound 
in soybean, inhibits activities of both P-gp and 
MRP2 (80, 81) . In vitro study conducted in human 
embryonic kidney (HEK) 293 cells stably expressing 
OATP-B (HEK/OATP-B cells) employing extracts 
of bilberry, enchinacea, green tea, banana, grape 
seed, gingkgo and soybean produced significant 
inhibition of OATP-B mediated uptake of estrone-3-
sulfate (82).  
In a recent study, 50 ml of ‘‘untreated’’ Red 
Yeast Rice aqueous extract (RYR) of a concentration 
0.5 mg/ml were added into the apical compartment 
of Caco-2 tissue culture plates in the presence of 
verapamil as a P-gp probe substrate. The study 
showed a 2-fold increase in the net absorption of 
verapamil from apical membrane to the basolateral 
compartment, an indicative of a potential inhibitory 
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effect of RYR on intestinal P-gp. A further study was 
conducted in intact animal to confirm the result from 
caco-2 cell line. The result showed 30 minutes post-
administration of verapamil in pre-treated 
“untreated” RYR rat models produced a 2-fold 
plasma concentration of P-gp probe substrate 
compared to the control which concurred with the 
outcome of the in vitro study (83). 
Ginseng is one of the most recognised traditional 
Chinese medicines reported to exhibit anticancer 
effect due to presence of 20(S)-Ginsenoside Rh2 
[20(S)-Rh2], a trace element in gingseng (84 ,85) . In 
2010, a study conducted by Zhang and others 
revealed that presence of 20(S)-Rh2 significantly 
reduced transport of three classical P-gp probe 
substrates; digoxin, fexofenadine, or etoposide 
across Caco-2 monolayers in basolateral to apical 
direction but increased digoxin or etoposide 
transport in the apical to basolateral direction. The 
result reveals that 20(S)-Rh2 inhibits efflux activity 
of P-gp whilst uptake transporters in the apical 
membrane are induced which could result in 
potential systemic toxicity of the substrates. Further 
study was conducted in Sprague-Dawley rats 
intragastrically treated with 20(S)-Rh2 in the 
presence of the three P-gp probe substrates as a 
follow-up investigation of the in vitro result. The 
outcome of this in vivo study revealed an increase in 
AUC and Cmax for all the substrates without any 
impact on their terminal elimination half-life. This 
suggests that the bioactive compound increase 
absorption of the substrates by inhibiting P-gp 
similar to that observed in the in vitro study (86). 
Oga and co-workers (2012) investigated the 
impact of herbal medicines used for treatment of 
malaria on P-glycoprotein mediated efflux in Caco-
2 cell monolayer in the presence and absence of 
digoxin (87). Their investigation showed a 
significant inhibition of digoxin from basolateral to 
apical membrane of Caco-2 cell monolayer when 
extracts from Vernonia amydalina, Carica papaya 
and Tapinanthus sessilifolius were independently 
applied. Thus, these herbal medicines may increase 
bioavailability of antimalaria drugs once 
concomitantly administered. The increase systemic 
circulation of antimalaria drugs could become toxic 
to the liver (88). 
Thus concomitant administration of herbs and 
drugs which are substrates for P-gp may either cause 
therapeutic failure and pre-systemic toxicity due to 
induction of the transporter or systemic toxicity as a 
result of inhibition of the efflux transporter. The role 
of in vitro cell culture systems in preclinical studies 
involving HDI therefore cannot be overemphasized. 
The Caco-2 cell is therefore often employed to assess 
functions of intestinal membrane transporters 
especially P-gp during HDI studies since most herbs 
are consumed orally. 
Common Pitfalls in Caco-2 Assays  
Variations in passive and carrier-mediated 
transports 
Pharmaceutically relevant uptake transport proteins 
(e.g. peptide transporters, organic cation transporter 
and OAT) are under-expressed in Caco-2 monolayer 
compared to the level of expression in vivo 
(89,90,91). Studies have demonstrated poor 
permeability of β-lactam antibiotics (e.g. cephalexin 
and amoxicillin) and ACE inhibitors across Caco-2 
cell monolayer although these dipeptide transporter 
substrates are completely absorbed in vivo (92) . 
Also, it has been shown that there is significant 
variation of mRNA expression levels of efflux 
transporters in Caco-2 cell monolayer compared to 
small and large intestines in humans. For example, 
the transcription of BCRP (ABCG2) is about a 100-
fold lower in Caco-2 cells compared with jejunum 
(99,93 ,94). The differences in transporter proteins 
expression in Caco-2 cell monolayer generate false 
negative findings that may not correlate with in vivo 
studies. 
The source of Caco-2 cell and inter-laboratory 
variations in protocol design contribute to 
discrepancies in paracellular permeability of 
compounds in the monolayer. Studies have shown 
that, the source of Caco-2 cell could provide a 100-
fold variation in the permeability of mannitol (95) 
and 20-fold differences in TEER due to different 
culture conditions and composition of cell 
subpopulation (30).  Inter-laboratory differences in 
TEER values influence the estimation of passive 
transport of compounds since the TEER value is used 
to determine the expression of tight junction. For 
instance, the low molecular weight hydrophilic 
compounds (e.g. metformin, ranitidine, atenolol, 
furosemide or hydrochlorothiazide) are well-
absorbed in humans.  However, poor permeability of 
these compounds has been observed in Caco-2 cell 
monolayer similar or even less than that of mannitol. 
This drug transport abnormality poses a problem to 
properly predicting the in vivo-in vitro correlation of 
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data from different laboratories due to variable 
outcomes.  
Low expression of CYP3A4 
Intestinal CYP3A4 plays a vital role in first pass 
metabolism of drugs and herbs. An ideal cell–based 
model for intestinal permeability studies should 
mimic the human gastrointestinal enterocytes by 
expressing metabolic enzymes together with the 
lipid bilayer interspersed with transporters and tight 
junctions to give a fair representation of the inter-
play between CYP3A4 and P-gp. The Caco-2 cell 
monolayer fails to simulate in vivo intestinal 
environment due to low expression of CYP3A4 
which is considered as the main drug-metabolizing 
enzyme in the human epithelial cells.  
Loss of compounds - Membrane retention and non-
specific binding 
Membrane retention also called cacophilicity refers 
to the tendency of a drug to reversibly bind to Caco-
2 cells causing incomplete recovery and inaccurate 
data interpretation. Incomplete recovery is especially 
common with lipophilic drug candidates. Several 
factors including:  the amount of drugs that appeared 
in the receiver compartment, the initial concentration 
in the donor compartment, and the surface area of the 
physical barrier (e.g, lipid bilayers and cell 
monolayer) affect permeability of drugs. The drug 
can also non-specifically bind to plastic devices 
(transwell plates), reducing the concentration of drug 
in the donor and receiver compartments during 
incubation period and therefore leading to 
underestimation of permeability estimates, and false 
negatives. Non-specific binding can also occur 
during transfer of cultured sample together with the 
drug into another container. Few approaches may be 
helpful to reduce this problem. The final donor 
concentration may be preferred to initial donor 
concentration at the termination of incubation since 
the non-specific binding occurs relatively faster. The 
second approach involves addition of bovine serum 
albumin to the receiver compartment to minimize 
non-speciﬁc binding of lipophilic drugs, thus, 
improve the assay recovery and overall predictability 
(96,97,98).  Application of organic solvent such as 
acetonitrile into containers ready to receive 
transferred cultures has also been helpful to reduce 
loss of compounds due to non-specific binding to 
plastic devices. 
Lack of adequate solubility 
The permeability assessment of test compounds in 
Caco-2 is underestimated due to poor aqueous 
solubility. Organic cosolvent such as DMSO and 
propylene glycol are added to the donor 
compartment to avert this problem. However, the 
Caco-2 cell monolayer can tolerate these organic 
solvent at a concentration ~1 - 2% v/v. Beyond this 
concentration, the cell tight junction is compromised 
and renders the monolayer impracticable. However, 
some solvents such as Tween 80, cremophor and 
pluronic which are known inhibitors of efflux 
transporters must be avoided  (99,100,101). 
Intestinal pH variations from the upper small 
intestine to the distal large intestine determine the 
nature of compounds absorbed at a specific region. 
For example, weak acidic drugs remain unchanged 
in the upper small intestine due to high pH, therefore 
passive transcellular transport emerge as the 
dominant route of absorption into the circulation. 
Caco-2 studies are incapable of simulating the 
changes of intestinal pH system since it is performed 
at constant pH conditions (apical pH of 6.5 and 
basolateral pH of 7.4). Any pH modification in 
design of Caco-2 cell protocol may affect its cyto-
architecture and underestimate the permeability 
characteristics.  
Other experimental variability 
Different laboratories operate under diverse 
experimental conditions such as culturing, passage 
number and culture duration which account for 
variations in permeability values. The inter-
laboratory variations affect the expression levels of 
efflux transporters which depend on the age of the 
cell cultures (19). The Caco-2 subclones expressing 
high levels of efflux transporters are currently 
preferred to establish structure-transport relationship 
for efflux transporters.  Few challenges have been 
encountered during analysis of samples using 
various instruments such as HPLC or LC-MS. These 
instruments are expected to produce accurate results 
due to their sensitivity. However, presence of high 
salt component in transport buffer (e.g. HBSS) 
interferes with ionization and hence complicates 
development of steady LC-MS methods.  
Current and future approaches 
Quality high throughput devices are employed by 
dedicated laboratories for screening large quantities 
of new drugs. Most of these new devices are 
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developed through integration of advance 
knowledge in molecular biology and combinatorial 
computer into conventional in vitro models. A few 
of these recent developments in Caco-2 cell 
permeability assay which may eventually replace the 
conventional techniques in the coming years are 
discussed below.  
Automation and Robotic systems 
Cell culturing requires several hours of repetitive, 
painstaking manual procedures in order to maintain 
absolute sterility. Additionally, maintenance of 
favourable environmental conditions via the cell 
culture cycle; growth, harvesting, re-seeding and 
analysis are important. Cell growth therefore 
demands careful regulation of several factors in an 
attempt to achieve viable and consistent Caco-2 cell 
lines. In conditions where large quantities of 
permeability assay of compounds are analysed, there 
is a high propensity of cell contamination. This 
difficulty has propelled pharmaceutical companies to 
embrace the use of automated Caco-2 cell culture 
system. An automated Caco-2 system can be 
employed to study 200-500 compounds within a 
month without any increase in the cost of operation. 
Robotic systems are capable of performing both 
the cell culture and high throughput screening assay 
of drug candidates. Most robotic systems perform 
multi-purpose tasks such as plate coating, seeding 
and cell feeding. The robotic system uses key 
components (articulating arms and plate carousel) to 
automate the cell culture procedure. The articulating 
arms hold plates at different angles allowing the user 
to dispense media on the wall of the plate, reducing 
possible cell or membrane damage (19).  
Ready-to-use Caco-2 models 
Modified Caco-2 cell models which are ready for 
permeability analysis within culturing time of 3-7 
days have been produced by dedicated laboratories 
to curtail the long period associated with parental 
culture procedure. Some of these modified models 
are currently used for permeability analysis of new 
drugs. Typical example of modified models, 
BiocoatTM HTS Caco-2 Assay System promotes 
rapid differentiation of Caco-2 cells. The system is 
accompanied by a specialized media formulation 
that facilitates differentiation of the cell monolayer 
within three days. Major pharmaceutical industries 
globally now depend on BiocoatTM HTS Caco-2 
Assay System for oral permeability evaluation of 
new drugs. CacoReadyTM is another innovative cell-
based and ready to use kit for intestinal permeability 
analysis. The kits composed of 24 and 96 insert-
integrated permeable supports seeded with 
differentiated and polarized Caco-2 barriers on 
polycarbonated microporous filters. A comparative 
study to assess permeability efficient of parental 
Caco-2 and BiocoatTM HTS Caco-2 assay system 
using parabens; a preservative commonly used in 
food, cosmetics and pharmaceutical industries 
showed better absorption in ready-to-use Caco-2 as 
illustrated by figure 4 (102). Ready-to-use Caco-2 
cell has several advantages over parental Caco-2: 
high flexibility, time saving and cost effective, easy 
to set up, high reproducibility and adaptable to 
automated procedures and high throughput 
screening. However, low expression of enzymes and 
transporters has been reported due to inadequate 
duration for culturing  (103,104).  
Transfected Caco-2 cell line 
The advances made in modern molecular biology 
and genetic information are exploited fully to 
enhance functional expression of transporters and 
CYP using Caco-2 cell lines. The expression level of 
specific transporters in Caco-2 may be manipulated 
either transiently or stably according to the 
preference of the researcher  (105). Construction of 
transfected Caco-2 cell line is relevant to transporters 
such as PEPT1 that cannot be expressed under 
normal culture conditions. In a study conducted to 
characterized the cellular uptake mechanism of 
amino acid ester prodrugs of nucleoside antiviral 
drugs in the transiently transfected Caco-2 cells 
overexpressing a human intestinal peptide 
transporter, hPEPT1 (Caco-2/hPEPT1 cells), the 
transfected cell line produced five times higher 
uptake than parental Caco-2 (106) . However, 
induction of efflux transporters is often easier and 
well-expressed in parental Caco-2 compared to 
transfected cells. Hence, transfection of efflux 
transporters in Caco-2 cell is not recommended. 
The Caco-2 cell line can also be transfected with 
extra-chromosomal CYP vectors. Caco-2 cells 
transfected with CYP3A4 have been successfully 
employed to investigate the interplay of CYP 
enzymes and efflux pumps at the intestinal 
epithelium  (107). Nevertheless, transfected Caco-2 
harbouring extra-chromosomal CYP have been 
withdrawn from the market due to its lack of long-
term stability.  
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Figure 4. comparative permeability assessment between parental and ready-to-use Caco-2 models using paraben adopted 
from Lakeram et al. (110).  
Molecular biology technology has been used to 
modulate the expression of nuclear receptors that are 
principal regulators of gene expression for CYP 
enzymes. Caco-2 cells transfected with human PXR 
and HNF4 genes showed an increased expression of 
both nuclear receptors under CYP3A4 promoter 
control  (108). 
The functional expressions of efflux and uptake 
transporters in Caco-2 monolayer depend on the 
passage number and other inter-laboratory 
conditions. These variations have resulted in 
inconsistent expression of drug transporter during 
permeability assays. In recent years, dedicated 
laboratories have introduced engineered cell lines 
which explicitly over-express a specific efflux or 
uptake transporter for better examination of drug-
transporter interactions. The newly constructed cell 
line selectively express transporter of interest and 
enhance interaction study with a specific transporter 
in isolation. Bidirectional investigations conducted 
in engineered Caco-2 cell line are devoid of 
interference from other transporter since only a 
specific transporter is teased out. The functional 
expression of transporters in transfected cell line 
appears more stable than parental Caco-2 cell.  
Knockdown Caco-2 cell line 
Selectively knocking down specific endogenous 
genes is an alternative to construct modified Caco-2 
cell line with a decreased transporter expression. 
Several attempts have been made to produce Caco-2 
cell lines deficient in P-glycoprotein. Hilgendorf  and 
co-workers were first to use antisense technique to 
reduce transcription and activity of P-gp. Currently, 
modern siRNA technology is employed to reduce P-
gp activity in Caco-2 cells. Although siRNA 
technology drastically reduced P-gp expression, 
conflicting results have been reported (109). Celius 
and others  (110) reported that complete abolishment 
of P-gp is unachievable whilst Watanabe and co-
workers (111) experiment produced complete loss of 
both MDR1 mRNA and P-gp expression. The 
application of siRNA technology in Caco-2 cell line 
must be done with caution to prevent 
misrepresentation of data.  
CONCLUSION 
The Caco-2 model is widely used as a tool for 
permeability and/or absorption screening of test 
compounds during decision-making process in the 
early stages of drug discovery. The use of Caco-2 
cell line for herb-drug interactions screening is 
increasingly gaining grounds in the academia and 
dedicated laboratories due to its popularity and 
acceptability. The recommendation of Caco-2 cell 
line by the FDA as an integral component of the 
Biopharmaceutics Classification System (BCS) has 
given this model an advantage over the other cell-
based models (112). Consequently, the routine 
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application of Caco-2 cell for screening of 
biopharmaceutical parameters of test compounds 
such as herbal medicines in dedicated laboratories 
requires reliable protocol to generate reproducible 
results. The pitfalls enumerated in this review may 
undermine the credibility of results generated from 
different laboratories due to protocol variations. 
However, the incorporation of current and future 
technologies discussed in this paper into Caco-2 cell 
line study protocol during herb-drug interactions 
investigations may reduce some of these caveats. 
The dedicated laboratories engaged in screening of 
herbs and NCE must therefore embrace the paradigm 
shift of the emerging technologies associated with 
the application of Caco-2. This will improve the 
reproducibility of results from different laboratories 
and help decision making bodies to give right 
recommendations for clinical trials based on the pre-
clinical information  
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Table 1. Selected important membrane transporters involved in intestinal drug absorption 
Transporter  Location Expression in 
Caco-2 cell 
line  
Substrates Inhibitors 
Tissue  Subcellular  
P-gp/MDR1(ABCB1) Intestine, liver, 
kidney, brain, 
placenta, adrenal, 
testes 
Apical + Digoxin,fexofenadine, indinavir, 
vincristine, colchicine, topotecan, 
paclitaxel 
Ritonavir,cyclosporine, 
verapamil,erythromycin, 
ketocoanzole,itraconazole, 
quinidine  
BCRP(ABCG2) Intestine, liver, 
breast, placenta 
Apical + Daunorubicin, doxorubicin, topotecan, 
rosuvastatin, sulfasalazine 
Elacridar (GF120918), gefitinib 
MRP1(ABCC1) Ubiquitous Basolateral  + Adefovir, indinavir ? 
MRP2 (ABCC2) Liver, intestine and 
kidney 
Apical + Indinavir, cisplatin, Cyclosporine, delaviridine, 
efavirenz, emtricitabine 
MRP3(ABCC3) Liver, intestine, 
kidney and bile 
ducts 
Basolateral + Etoposide, methotrexate, tenoposide Delaviridine, efavirenz, 
emtricitabine 
MRP4 (ABCC4) Prostate, lung, 
muscle, pancreas 
and bladder 
Apical + Adefovir, tenofovir, methotrexate, 
topotecan 
Celecoxib, diclofenac 
MRP5(ABCC5) Ubiquitous Basolateral + ? ? 
MRP6(ABCC6) Liver and kidney Basolateral + Cisplatin, daunorubicin ? 
PepT1(SLC15A1) Intestine, kidney Apical  + Ampicillin, amoxicillin, captopril, 
valacyclovir 
Glycyl-proline 
OATP 2B1(SLCO2B1) Intestine, liver, 
kidney, brain 
Apical  ? Pravastatin Rifampicin, cyclosporine 
MCT1(SLC16A1) Intestine, 
erythrocyte 
Apical  + ? ? 
Keys: += presence and ? = unknown 
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Table 3. Comparison of Caco-2 with other cell-based models for intestinal permeability studies 
Cell lines Origin Specific characteristics  Strengths  Weaknesses References 
Caco-2 Human colon 
adenocarcinoma 
Most established cell model 
Spontaneous differentiation and 
expression of some relevant 
efflux transporters 
Interlaboratory variations in 
expression of uptake transporters 
Well developed and 
characterized  
Easy maintenance 
Good reproducibility, 
robustness and functional 
property of human 
intestinal cells. 
Extensively used, large 
database available 
Absence of mucous secreting 
goblet cells 
Not suitable for paracellular 
transport 
Low expression of metabolizing 
enzymes 
21-days culture period 
(i, 78) 
HT29-MTX Human colon Contains mucus-producing 
goblet cells 
Expression of mucin Not suitable for carrier-mediated 
transport 
Unstable mucus layer 
(ii, iii) 
LLC-PK1 Pig kidney Polarized cells with low intrinsic 
transporter expression 
Suitable for transfections 
Characterization of passive 
transport 
Absence of P-gp (65, 67) 
J Pharm Pharm Sci (www.cspsCanada.org) 17(1) 1 - 19, 2014 
19 
MDCK Dog kidney Polarized cells with low intrinsic 
expression of efflux transporters 
Suitable for transfections 
3-5 days culture period 
Ideal for transfection 
purposes 
Under-expression of major 
efflux transporters 
High expression of CYP 3A5 
and less of CYP 3A4 
(iv, v) 
TC7 Caco-2 subclone Low expression of P-gp 
Stable expression of CYP3A4 
High taurocholic acid transport 
High CYP 3A4 expression Similar to Caco-2 (vi) 
2/4/A1 Rat fetal intestinal 
epithelial cells 
Temperature-sensitive 
Suitable for paracellularly 
absorbed compounds (leakier 
pores) 
Produces tight junction 
similar to human intestine 
Expression of both 
transporters and 
metabolizing enzymes 
Low expression of protein  
Good for medium to low 
throughput screening.  
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